| OALBE0104 | What women want - results from discrete choice experiment about preferred PrEP method from Khomas region of Namibia | Oral abstract session with live Q&A | Implementation science of scaling up prevention (including PrEP) |
| OALBE0103 | A tale of two countries: assessing the transition, scale-up, and sustainability of HIVST introduction in India and Indonesia | Oral abstract session with live Q&A | Implementation science of scaling up HIV testing |
| OALBE0102 | SEARCH-Youth: a cluster randomized trial of a multilevel health system intervention to improve virologic suppression in adolescents and young adults living with HIV in rural Kenya and Uganda | Oral abstract session with live Q&A | Making health systems work for adolescents |
| OALBD0105 | Assessing stigma as determinant of HIV and sexually transmitted infections among sexual minority men in the United States in 2021 from the American Men's Internet Survey (AMIS) | Oral abstract session with live Q&A | Gay men other men who have sex with men |
| OALBD0104 | A community-based participatory approach to understanding preferences, needs, and barriers to uptake of longer-acting formulations of PrEP in transgender and gender diverse Texans | Oral abstract session with live Q&A | Transgender people |
| OALBD0102 | Understanding COVID-19 vaccine confidence in people living with HIV in Canada: a pan-Canadian survey | Oral abstract session with live Q&A | Social and behavioural aspects and approaches to COVID-19 |
| OALBC0105 | Predictors of high viral load among adult HIV recipients of care in Zambia, 2021: a cross-sectional analysis of HIV case-based surveillance data | Oral abstract session with live Q&A | Epidemiology of HIV in the general population |
| OALBC0104 | National roll out of community HIV screening among key populations in Indonesia: assessment of early results | Oral abstract session with live Q&A | HIV self-testing |
| OALBC0103 | A phase IV open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to HIV-1 | Oral abstract session with live Q&A | Demonstration and pilot projects for prevention (including PrEP, PEP, male circumcision) |
| OALBC0102 | High prevalence of asymptomatic Omicron carriage and correlation with CD4+ T cell count among adults with HIV enrolling in COVPN 3008 Ubuntu clinical trial in sub-Saharan Africa | Oral abstract session with live Q&A | Epidemiology of COVID-19 among persons living with HIV and / or including tuberculosis |